MIRA
INFORM REPORT
|
Report Date : |
13TH
June, 2006 |
IDENTIFICATION
DETAILS
|
Name : |
INTAS
PHARMACEUTICALS LIMITED |
|
|
|
|
Registered Office : |
2nd Floor, Chinubhai Centre, Off Nehru Bridge, Ashram Road,
Ahmedabad – 380 009, Gujarat, India |
|
|
|
|
Country : |
India |
|
|
|
|
Financials (as on) : |
31.03.2005 |
|
|
|
|
Date of Incorporation : |
31.05.1985 |
|
|
|
|
Com. Reg. No.: |
04-7866 |
|
|
|
|
CIN No.: [Company
Identification No.] |
U24231GJ1985PTC007866 |
|
|
|
|
TAN No.: [Tax
Deduction & Collection Account No.] |
AHMI00350A |
|
|
|
|
PAN No.: [Permanent
Account No.] |
AAACI5120L |
|
|
|
|
Legal Form : |
A
closely held public limited liability company |
|
|
|
|
Line of Business : |
Manufacturing and Exporting of Medical
Formulations in the key Therapeutic Segments of Cardiovascular,
Neuropsychiatry, Gastroenterological, Antibacterial and Dermatological
Products. |
RATING & COMMENTS
|
MIRA’s Rating : |
A |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
56-70 |
A |
Financial & operational base are
regarded healthy. General unfavourable factors will not cause fatal effect.
Satisfactory capability for payment of interest and principal sums |
Fairly Large |
|
Maximum Credit Limit : |
USD
6500000 |
|
|
|
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Usually Correct |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject
is a well established and one of the fastest growing pharmaceutical companies
in India. The company’s track are fine. Banking relations are good. The
company is making steady progress in its turnover and profits and products
line. Trade relations are fair. Payments are usually correct and as per
commitments. The
company can be considered good for business dealings at usual trade terms and
conditions. |
LOCATIONS
|
Registered Office : |
2nd Floor, Chinubhai Centre, Off Nehru Bridge, Ashram Road,
Ahmedabad – 380 009, Gujarat, India |
|
Tel. No.: |
91-79-26576655/26579052/26578269 |
|
Fax No.: |
91-79-26588862/26578862 |
|
E-Mail : |
|
|
Website : |
|
|
|
|
|
Corporate
Office : |
Chinubhai Centre, Off. Nehru Bridge, Ashram Road, Ahmedabad – 380 009,
Gujarat, India |
|
Tel.
No.: |
91-79-26576655 |
|
Fax
No.: |
91-79-26578862 |
|
|
|
|
Factory
1 : |
Matoda Factory
Vatva Factory
|
DIRECTORS
|
Name : |
Mr.
Hasmukh K. Chudgar |
|
Designation : |
Chairman and Managing Director |
|
Date of Birth/Age : |
16.06.1933 |
|
Qualification : |
B. Pharm |
|
Experience : |
44 years |
|
|
|
|
Name : |
Dr.
Urmish Chudgar |
|
Designation : |
Director |
|
Date of Birth/Age : |
16.02.1959 |
|
Qualification : |
M.D. - Oncology & Haematology |
|
Experience : |
15 years (Was Medical Practitioner, by
profession upto 01.04.1994) |
|
|
|
|
Name : |
Mr.
Nimish H. Chudgar |
|
Designation : |
Director |
|
Date of Birth/Age : |
19.07.1960 |
|
Qualification : |
B.Sc. |
|
Experience : |
17 years |
|
|
|
|
Name : |
Mr.
Binish H. Chudgar |
|
Designation : |
Director (International Business) |
|
Date of Birth/Age : |
01.12.1963 |
|
Qualification : |
B. Com., MBA |
|
Experience : |
13 years |
|
|
|
|
Name : |
Mr.
Dilip K. Patel |
|
Designation : |
Director (Financial Institution Nominee) |
|
Date of Birth/Age : |
20.10.1947 |
|
|
|
|
Name : |
Mr. Nitin
J. Deshmukh |
|
Designation : |
Director |
|
Date of Birth/Age : |
7th November, 1962 |
KEY EXECUTIVES
|
Other personnel |
|
MAJOR SHAREHOLDERS
The
company's entire (100%) share capital is held by the Directors and their
relatives only
|
Names
of Shareholders |
Percentage of Holding |
|
Equatorial Limited |
57.60% |
|
TDICI |
12.47% |
|
SICOM |
4.99% |
|
Directors |
22.94% |
|
Family Members |
2.00% |
BUSINESS DETAILS
|
Line of Business : |
Manufacturing and Exporting of Medical
Formulations in the key Therapeutic Segments of Cardiovascular,
Neuropsychiatry, Gastroenterological, Antibacterial and Dermatological
Products. |
|
|
|
|
Products : |
v
Tablets v
Injectables v
Capsules v
Bulk
Drugs |
|
|
|
|
Exports to : |
Kenya,
Tanzania, Trinidad, Thailand, Mauritius, Sri Lanka, Malaysia, Russia,
Netherlands, UK and West Indies. |
|
|
|
|
Imports from : |
Trinidad,
Mauritius, Sri Lanka, Europe, USA, Italy, Germany, Spain and Hong Kong |
|
|
|
|
Terms : |
|
|
Purchasing : |
L/C,
D/A and CAD terms |
GENERAL
INFORMATION
|
Suppliers : |
v
Chemo
Iberica S. P. A. of Spain v
Chumann
Pharma GmbH of Germany v
Bayron
Chemicals of USA v
Laboratory
MAG S.P.A. Milano, Italy v
Vis
Pharmaceuticals, Italy v
Vertex
Chemicals of HongKong |
|
|
|
|
Customers : |
v
Trinpharma
Company Trinidad v
Fair
Trade of Mauritius v
Throngroup
Private Limited, Sri Lanka |
|
|
|
|
No. of Employees : |
515 |
|
|
|
|
Bankers : |
v
State
Bank of India, Commercial Bank, Main Branch, Ahmedabad, Gujarat, India v
Corporation
Bank, Navrangpura Branch, Ahmedabad, Gujarat, India v
UCO
Bank, Bhadra Branch, Ahmedabad, Gujarat, India v
Exim
Bank of India, Cuffe Parade, Mumbai - 400 005, Maharashtra, India v
IDBI,
Ahmedabad, Gujarat, India |
|
|
|
|
Facilities : |
-- |
|
|
|
|
Banking Relations : |
Satisfactory |
|
|
|
|
Auditors : |
Apaji
Amin & Company Chartered
Accountants |
|
Address: |
Khanpur,
Ahmedabad - 380 001, Gujarat, India |
|
Tel. No.: |
91-79-2303603 |
|
|
|
|
Associates/Subsidiaries : |
Intas Exports Active in the export of medical formulations to Europe, Asia Pacific
and Africa International Pharmaceuticals Subject is a proprietory concern. Engaged as Manufacturer Viresh Corporation Subject is a proprietory concern. Acts as traders Intas Distributors Subject is a proprietory concern. Acts as traders Zen Enterprises Subject is a proprietory concern. Acts as traders BNB Enterprises Subject is a proprietory concern. Acts as traders Astron Packaging Limited Astron Research Limited Equatorial Private Limited Lambda Therapeutic Research Limited Epsilon Marketing and Consultancy Private Limited Intas Finance Private Limited Celestial Biological Limited Advanced Transfusion Medicine Research Foundation One Advertising and Communication Services Limited Cytas Research Limited subsidiaries
v
Andre Laboratories Limited v
Indus Biothrapeutics Limited v
Accord Healthcare Limited v
Accord Healthcare Limited, UK v
Accord Healthcare Limited, USA |
CAPITAL STRUCTURE
Authorised
Capital :
|
No.
of Shares |
Type |
Value |
Amount |
|
10,000,000 |
Equity Shares |
Rs. 10/- each |
Rs. 100.000 millions |
Issued,
Subscribed & Paid-up Capital :
|
No.
of Shares |
Type |
Value |
Amount |
|
4660000 |
Equity Shares |
Rs. 10/- each |
Rs. 46.600 Millions |
FINANCIAL DATA
[all figures are in Rupees
Millions]
ABRIDGED
BALANCE SHEET
|
SOURCES OF FUNDS |
31.03.2005 |
31.03.2004 |
31.03.2003 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
46.600 |
40.100 |
40.100 |
|
|
2] Share Application Money |
0.000 |
0.000 |
0.000 |
|
|
3] Reserves & Surplus |
1610.800 |
952.816 |
737.800 |
|
|
4] (Accumulated Losses) |
0.000 |
0.000 |
0.000 |
|
|
NETWORTH |
1657.400 |
992.916 |
777.900 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
1161.300 |
1137.988 |
1060.000 |
|
|
2] Unsecured Loans |
222.600 |
83.586 |
125.100 |
|
|
TOTAL BORROWING |
1383.900 |
1221.574 |
1185.100 |
|
|
DEFERRED TAX LIABILITIES |
0.000 |
225.628 |
0.000 |
|
|
|
|
|
|
|
|
TOTAL |
3041.300 |
2440.118 |
1963.000 |
|
|
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
1936.100 |
1061.210 |
1055.200 |
|
|
Capital work-in-progress |
0.000 |
202.520 |
0.000 |
|
|
|
|
|
|
|
|
INVESTMENT |
84.100 |
68.719 |
66.000 |
|
|
DEFERREX TAX ASSETS |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
|
|
Inventories |
949.000
|
858.684 |
781.800 |
|
|
Sundry Debtors |
598.200
|
526.933 |
517.500 |
|
|
Cash & Bank Balances |
66.800
|
79.966 |
102.500 |
|
|
Other Current Assets |
0.000
|
0.000 |
0.000 |
|
|
Loans & Advances |
361.800
|
177.018 |
151.900 |
|
Total Current Assets |
1975.800
|
1642.601 |
1553.700 |
|
|
Less : CURRENT LIABILITIES & PROVISIONS |
|
|
|
|
|
|
Current Liabilities |
931.800
|
540.212 |
731.900 |
|
|
Provisions |
39.700
|
22.484 |
19.600 |
|
Total Current Liabilities |
971.500
|
562.696 |
751.500 |
|
|
Net Current Assets |
1004.300
|
1079.905 |
802.200 |
|
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
16.800 |
27.764 |
39.600 |
|
|
|
|
|
|
|
|
TOTAL |
3041.300 |
2440.118 |
1963.000 |
|
PROFIT
& LOSS ACCOUNT
|
PARTICULARS |
31.03.2005 |
31.03.2004 |
31.03.2003 |
|
Sales Turnover [including other income] |
4614.100 |
3886.327 |
3035.500 |
|
|
|
|
|
|
Profit/(Loss)
Before Tax |
394.400 |
325.176 |
242.700 |
|
Provision
for Taxation |
109.300 |
95.486 |
68.900 |
|
Profit/(Loss)
After Tax |
285.100 |
229.690 |
173.800 |
|
|
|
|
|
|
Total
Expenditure |
4085.400 |
3561.151 |
2792.800 |
KEY
RATIOS
|
PARTICULARS |
31.03.2005 |
31.03.2004 |
31.03.2003 |
|
Debt
Equity Ratio |
0.98 |
1.36 |
1.37 |
|
Long
Term Debt Equity Ratio |
0.98 |
1.36 |
1.37 |
|
Current
Ratio |
2.05 |
2.07 |
2.38 |
|
TURNOVER
RATIOS |
|
|
|
|
Fixed
Assets |
2.84 |
3.05 |
2.89 |
|
Inventory
|
5.03 |
4.62 |
3.94 |
|
Debtors |
8.08 |
7.25 |
6.38 |
|
Interest
Cover Ratio |
4.96 |
3.73 |
3.28 |
|
Operating
Profit Margin (%) |
13.83 |
13.41 |
13.23 |
|
Profit
Before Interest and Tax Margin (%) |
10.88 |
11.53 |
11.91 |
|
Cash
Profit Margin (%) |
9.23 |
7.79 |
7.25 |
|
Adjusted
Net Profit Margin (%) |
6.28 |
5.91 |
5.93 |
|
Return
on Capital Employed (%) |
18.96 |
21.25 |
19.78 |
|
Return on Net Worth (%) |
21.51 |
25.30 |
22.89 |
LOCAL AGENCY
FURTHER INFORMATION
HISTORY
The
company was incorporated on 31st May 1985 at Ahmedabad in Gujarat
under the name and style of Intas Laboratories Private Limited having Company
Registration Number 7866. It became a
deemed public limited liability company with effect from 29.03.1995.
The name
was changed to the present somewhere in the year 1996.
The
Group commenced with trading activity in 1964 and went into manufacturing in
the year 1976.
The unit
no. 2 at Matoda on Sarkhej Bavla Highway is a Rs. 150 millions project for
manufacturing of all range of pharmaceutical formulations and bulk drugs.
The
plant at Vatva was functioning on a loan lease basis from 13.07.1999.
With the
leadership in the field of gastroenterology and neuro-psychiatry, the company
has become one of the leading pharmaceuticals groups in India since 1976.
With a
strong Formulation Development facility, several innovative formulations have
been developed for the first time in India which include Nilol (Film Coated
Tablets of Nifedipine Sustained Release 20 mg + Atenolol 50 mg), Zolax – SR
(Sustained Release tablets of Alprazolam 1.5 mg), Ciza-MPS (The latest
prokinetic cisapride + Simethicone), Zen Retard (Controlled Release formulation
of Carbamazepine) and Nimotas – CD (Nimesulide tablets in Chewable +
Dispersible form).
Subjects
strength is its strong R&D and Modern packaging to suit customers
requirements. Several products like Mefloqiune, Amlodipine, Naltrexone &
Lomefloxacin are available in coldforming ALU-ALU packs.
OPERATIONS :
The year 2002-2003 has seen Intas graduating in its business operationsshowing
a growth of 32% taking it to 26th position in the IndianPharmaceutical
industry. This has provided us with leverage to surge aheadwith confidence in
their future endeavors. The Company continues to focus onCardiovascular,
Neuropsychiatry and Gastroenterological & Pain managementtherapeutic
segments.
Domestic Business :
The Company was triumphant in withstanding the stiff competition faced
fromcompetitors in marketing its products and has shown good results
inregistering a sales growth of 32% in the year 2002-2003 in the domesticmarket
against the industry growth of 6% (as per the ORG MARG Report March,2003). The
CNS, Cardiovascular and Gastroenterological have contributed toaround 75% of
the domestic sales. Their share in the domestic pharmaceuticalindustry has also
grown to 1.13% from last year's 1.02'%.
International Business :
The thrust on international business was carried forward with greater
paceand intensity during the year 2002-03. The unique array of
regulatoryapprovals from advanced regulatory authorities was further enhanced
withaddition of approval from ANVISA, Brazil. The opportunities in Biotech
andOncology products would give a further momentum to their growth
ininternational markets in the near future.
NEW PROJECTS :
Biotechnology :
With experience in marketing bio-generics and hepatitis-B vaccine
indomestic market, Intas has decided to install dedicated
manufacturinginfrastructure for development, manufacture and marketing
ofpharmaceuticals products obtained through "recombinant DNA"
biotechnology.The total cost of the project has been estimated at Rs 350.000
crores and Rs265.000 crores have already been spent on the project till 31st
March 2003.The maiden product would shortly undergo Phase III clinical trial
and isslated to hit the domestic market by 4th quarter of Year 2003-04.
Inrespect of other two products the Company has received permission to carryout
animal toxicity studies.
Oncology :
Having launched formulations in high-end cancer therapy for domestic
marketover past two years, Intas has decided to give a significant
internationalthrust to this business by setting up a dedicated plant for
manufacturingoncology products at its Matoda unit. As these products are
Cyto-toxic innature, the formulations of these molecules are manufactured based
on thebarrier isolation technology. The oncology plant has already
beensuccessfully commissioned in March, 2003 and the commercial production
atplant has begun.
It is
in trade terms with:
v
Chemo
Iberica S.P.A., Spain
v
Chumann
Pharma GmbH, Germany
v
Bayron
Chemicals, USA
v
Laboratory
Mag S.P.A., Milano, Italy
v
Vis
Pharmaceuticals, Italy
v
Vertex
Chemicals, Hong Kong
v
Trinpharma
Company, Trinidad
v
Fair
Trade, Mauritius
v
Thron
Group Private Limited, Sri Lanka
v
Dr.
Reddy’s Laboratories, Hyderabad, Andhra Pradesh, India
v
Bharat
Biotech International Limited, Hyderabad, Andhra Pradesh, India
v
Shashun
Drugs & Chemicals Limited, Chennai, Tamil Nadu, India
v
Hetero
Drugs Limited
The
company is a Registered Small Scale Industry.
It has
launched 'Typho-Vi, a typhoid vaccine and a high-tech oncology segment with
Cytax, anti cancer product, which was introduced in collaboration with Samyang
of Korea.
Neovet -
The veterinary division of the company ranks among the top 25 animal healthcare
companies in India. It launched
Mammitel, an anti-mastitis drug in collaboration with Biove Laboratories of
France.
Neovet,
the animal healthcare division of Intas
projects the vision of the new millenium and aims at a perfect partnership with
veterinary profession and farming community.
With the
introduction of the highest quality formulations for a variety of ailments of
large and small animals, it has already made a significant progress in the
Indian Veterinary Pharmaceutical Market.
Professional ethics and relationship is the hallmark of Neovet as it strives to
understand the basic needs of the veterinarians, farmers, business partners and
its employees.
In the international market the company has presence in more than 30 countries
and during the year the company made 200 submissions and registered 61
additional products in 15 countries.
The
company has tie-up with Sanofi Winthrop Limited.
The
company is exclusively focusing on the specialised cardiovascular, neurological
and gastroenterological therapeutic segments and achieving a leadership
position in these key segments.
The
company has strategic alliance with :
- MEB, The Netherlands
- TGA, Australia
- MCC, South Africa
- MCA, UK for veterinary
products
- AFI, Belgium
- FDA, Nordic Countries
- Anvisa, Brazil
Fixed
Assets
v
Land
v
Building
v
Plant
and machinery
v
Furniture
& Fixture
v
Office
equipment
v
Vehicle
v
Computers
As
per Website Details:
Genesis
Decades ago, an enterprising young Medical Representative, H
K Chudgar, dreamt of providing quality healthcare products to his country. At a
time when India imported even foodgrains, this visionary wanted to manufacture
world class medicines in the country. Armed with a degree in Pharmacy, this
budding entrepreneur set up shop as a pharma trading agency in the 1960s and
thus was Intas born.
Intas growth chart
|
1960s |
International
Trading Agency, the genesis of Intas |
|
1970s |
Vatva
plant, a small scale manufacturing unit |
|
1980s |
National
distribution channel set up First
successful molecule launched |
|
1990s |
Consolidation
and expansion Leadership
in the domestic market Entry
into the international market |
Never
one to tread the beaten path, Mr. H K Chudgar decided to focus on niche
therapeutic segments at a time when all others concentrated on the mass
markets. Success for Intas came in the form of an anti-depressant that took the
medical community by storm and then there was no looking back!
Mr.
Nimish Chudgar, Mr. Binish Chudgar and Dr. Urmish Chudgar joined the management
team and together they led Intas into the psychiatric, neurological, cardiac
and gastroenterological segments. So successful was this strategy of focusing
on speciality segments that today Intas is among the fastest growing
pharmaceutical companies in India.
As
Intas grew and diversified into newer areas, Mr. H K Chudgar brought in a
professional management team to help implement his Vision and today Intas reaps
the twin benefits of entrepreneurial vision and professional management. This
dynamic leadership has set the agenda for growth and Intas has been achieving
an average annual growth of over 30% since 1990 with the turnover crossing the
Rs. 1000 million mark in 1999. At the end of the financial year in 2001 it has
increased to Rs. 1800 million.
Intas today
Today, Intas is among the fastest growing pharmaceutical
companies in India. They have been meteorically progressing up the ORG-MAT
rankings, the barometer of success in the Indian pharmaceutical industry. They
have jumped from the 49th rank in end of 1998 to 24th position today.
Quality Procedure
Quality is a not a departmental obligation. It is
significant to everything and everyone in the organisation. To ensure Total
Quality Management, the Quality Assurance (QA) department in their factory is
autonomous in its functioning.
In-house quality checks, which are detailed in their Standard Operating
Procedures (SOP), have been drawn up in addition to the recommendations
specified in the US, British & Indian Pharmacopoeias for each of their
operations commencing from the raw material audit to in-process checks through
finished product inspection
Raw materials are accepted for manufacturing only after it is found to be of
international grade by their in-house and independent laboratories.
Their in-house bio-equivalence centre has been set up to conduct in-house
studies as well as to expedite experiments pursued by academic and research
institutes.
Corporate
Culture
Concern
for quality is at the core of all their activities. They aim to improve the
quality of life, not only in their own country, but worldwide. Indeed, they are
striving to build a Global Company, a world leader in life sciences, and to be
the very best in each of their activities.
At
Intas, they have made innovation a way of life. Innovation in products; in
technology; in packaging; in their business practices. In the recent years,
Intas has introduced into the Indian market various innovations like new drug
delivery systems, extended release molecules, recombinant vaccines and ALU-ALU
packaging.
Fuelling
their innovative practices is a genuine desire to provide customised solutions
to suit their customers' needs and to develop true partnerships with them. They
work relentlessly to provide their customers exactly what they need. With no
compromise. And in the process, they are creating a company where men and women
are proud to work and who find in their work, opportunities commensurate with
their commitment.
Facility
....Technology Finesse
An
obsession to “make the best better” has resulted in their setting up a highly
sophisticated manufacturing plant acclaimed as one of the finest in South East
Asia. This plant is WHO approved and meets US FDA standards.
The
manufacturing speed & capacity of their most modern plant ensure regular
supply of quality drugs to the domestic & international market. It is
equipped with High Efficiency Purified Air (HEPA) technology which maintains a
continuous flow of filtered air inside the plant, thus providing an absolutely
dust free sterile environment. Moreover, the fully automated facilities, with
an electronically monitored environment ensure zero contamination. They thus
successfully extend the benefits of modern technology to provide newer &
better health care services to mankind.
Approved
by
v
MCA,
UK
v
TGA,
Australia
v
MCC,
South Africa
v
MEB,
Netherlands
v
AFI,
Belgium
v
FDA,
Nordic Countries
v
Anvisa,
Brazil
Plant
Details
v
Total plot area: 105,000 sq. m
v Total
Built up area: about 32,000 sq. m
v Total area
of Solid Oral: about 2,100 sq. m
v Total area
of Parenterals: about 2,100 sq. m
Current
Capacity
Ampoules (1ml to 10 ml): 0.28 million units per
day :: 85 million units per
year
Vials: 0.1
million units per day :: 30
million units per year
Manufacturing
Flexibility
Manufacturing batch sizes from 60 kg to to 1000 kg per batch
Coating
load - from 22 kgs to 300 kgs
Environmental
Control
- Solid Orals Area
- 26 H.V.A.C. systems
- 18 Dust Extraction Systems
- Liquid Injectables
- 8 H.V.A.C. systems
Automation of packaging
Semi-automatic Cartonator: Vertopack
Automatic Cartonator
All Cartonator fitted with Leatus
pharma code scanning system for cartons and PILs
In the pipeline…
Setting up a Pallet Manufacturing facility comprising:
- Extruder
- Spheronizer
- Fluid Bed Drier / Wruster
- Fillers
- Dry syrup and Capsules Dosage forms to
be manufactured
- Fully functional by February 2004
- Expansion of Oral Solids Manufacturing
Upgraded
capacity:
- 18 million units of avg. wt. 500 mg in
a single day
- 5.4 billion units in a year
Their Strengths
- Well versed in handling contract
manufacturing projects for European companies
- Large capacities to produce bulk
quantities of Oral Solids
- Innovative and sophisticated Packaging
facilities
- Commitment to Excellence and Quality
- Dedicated and committed team of
professionals
- 200 experts in Manufacturing, QC and QA
HRD
Their
people will lead us into the next millenium. The values, ethics, interpersonnel
chemistry and congenial work environment makes this organisation a cohesive,
articulate and goal- directed unit.
At
Intas, they constantly redefine excellence and their vision beckons us to forge
ahead and achieve higher peaks. Intelligence, integrity, courage, imagination,
self-respect, and a sense of belonging are qualities not in short supply in
their company.
Their
culture encourages us to perform Herculean feats. They set their own goals and
constantly strive to surpass them. Their personal and professional achievements
are lauded, and amply rewarded. And if ever they need a helping hand, their HRD
team is ready to support us with refresher courses and need based training
programmes.
In
the midst of their achievements, they never forget that they are a team. They
exist not to compete against each other, but strive together to conquer newer
horizons. In their journey to excellence, they take the time to get to know
each other and share a few warm moments.
They
are a dynamic team; excited about their basic purpose; and they share a common
set of values. These values, vision, and mission form the core of their
identity; an identity that keeps each Intasian and the entire Intas team always
responsive and innovative in new situations.
Marketing
Domestic Marketing
Intas'
marketing set up is geared to cater to the requirements of different specialty
segments.
Intas
division markets Gastroenterologicals, Antibacterials,
Dermatologicals, and other related products. It has launched a recombinant
vaccine for Hepatitis B as also a Typhoid vaccine. This division has various
brand leaders e.g. Ciza, Lan-30 and Zopicon.
Altima is the
division focussing exclusively on Neurological and Psychotropic products. Zen,
Valprol CR, Zolax and Risdone feature among its success stories.
Aquila is a
recently launched neuro-psychiatry division operating parallely with Altima. It
aims to cater to the specialised requirements of neurosurgeons and
psychiatrists.
Suprima focuses
on the marketing of Cardiovasculars. Among its most successful brands are Amtas
and Monit.
They
have made a decisive entry into the hi-tech oncology segment with their Novatech
division launching Cytax, a revolutionary anti-cancer product. Aloric,
Clogen lozenges and Itaspor capsules are their supportive care products.
Optima, is
focussed at emerging as a leader in the ophthalomology segment. Among its
leading brands are Andre I-kul, Andre Eyedrops and Cyclogyl.
Neovet, their
veterinary division ranks among the top 20 animal healthcare companies in
India. It markets a range of antibiotics, tonics (injectibles), analgesics,
anti-pyretics, corticosteroids, antihistaminics, tranquillisers, and
chemotherapeutic agents. Neovet has launched Mammitel, a pioneering
anti-mastitis drug, in collaboration with Biove Laboratories, France.
Intas
Generics has emerged among the top 10 generic marketers in the Indian
pharmaceutical sector. With its reputation of being a reliable provider of
quality products, the Generics Division is set to exploit the opportunity
offered by the emerging generics market.
Country wide reach
To facilitate easy availability of their brands across the
nation, they have created a countrywide distribution network of C&F agents
& stockists who provide excellent support to the sales personnel. Their
young and dynamic field force of more than 1000 provides us with a strong
national presence.
International Marketing
Intas
has an international presence with around 20% of the current turnover coming
from foreign markets, including exports to Latin America, East Asia, etc. and
contract manufacturing for companies in Europe.
Intas
intends to enhance its global presence by leveraging on its technology
strengths and the quality of its products. It will also initiate marketing
operations in developed markets with the objective of achieving a critical
mass. Intas is initially exploring marketing tie-ups with local players of
developed markets. It intends to form strategic business units to spearhead its
operations in the US, the UK & the rest of Europe.
Intas
products are available in…
·
Europe
·
Africa
·
Latin American Region
·
South East Asia
·
Russia
·
CIS Countries
Regulatory approvals from...
·
MCA, UK
·
TGA, Australia
·
MCC, South Africa
·
MEB, Netherlands
·
AFI, Belgium
·
FDA, Nordic Countries
·
Anvisa, Brazil
R
& D
Intas
has embarked on an intensive program for development & analytical testing
of new formulations including biotech formulations, with the objective of
partnering with top multi-nationals for formulation research and providing
regulatory support. An independent facility, equipped with modern technology
and manned by professionals of the highest caliber, is the focal point of this
initiative.
In
the field of transfusion medicine, they have collaborated with the Technology
Development Board (Govt. of India) to develop two protein derived products -
fibrin glue and lyophilized cryoprecpitates.
Innovative
track record
At Intas, they have made innovation a way of life. Innovation in
products, technology and even in packaging. Intas was amongst the first
companies to introduce new drug delivery systems in some of its formulations
(like melt in mouth technology for Domperidone, sustained release Alprazolam,
once daily dosage for Isosorbide5 Mono Nitrate and controlled release Sodium
Valprolate). Intas also brought novel packaging to India through its
investments in ALU-ALU and cold blister packaging technology. Building on these
competencies, they are continuing to be at the forefront of innovation
research.
Strong
formulation development research capabilities
Intas’ current research and development focus on formulation research.
The Formulation research facility is equipped with equipments identical to
those in the manufacturing area, but scaled to accomodate one-tenth of
production batch size. This significantly facilitates transfer of technology
from Research and development to production. Formulations developed in R&D
center are subjected to accelerated stability testing as per international
norms. Analytical research laboratory develops stability indicating assay
methods to analyze related substances and degraded components.
Enhancing
capabilities in formulation research and development
Intas has embarked on an intensive program for development &
analytical testing of new formulations including biotech formulations, with the
objective of partnering with top multi-nationals for formulation research and
providing regulatory support. An independent facility, equipped with modern
technology and manned by professionals of the highest caliber, is the focal
point of this initiative.
Biotechnology
research
Intas entered the biotech foray in early 2000 with the vision to
establish Intas as a research based manufacturer of quality biopharmaceuticals
and become a significant global player in the bio-generics market. They are
transforming their vision into reality through investments in human resources
and infrastructure. A state-of-the-art research and manufacturing facility for
both bulk and finished biopharmaceutical product complements the expertise of
the multi-disciplinary R&D team with over 15 manyears of international
experience.
The
first product from this venture is likely to be launched by late 2003.
Excellence in every aspect
With their committed approach and their continuing focus on research and
innovation, they have succeeded in bringing international standards to the
domestic formulation market. They have come to be recognised as a dynamic organisation
that put up a world class formulation unit in the shortest possible time and
compelled other companies to benchmark us as excellence in manufacturing.
Its’
products range includes:-
|
CIZA TABLETS |
|
CIZA SUSPENSION |
|
CIZA - 20 |
|
CIZA - MPS |
|
LAN - 30 |
|
LAN - 15 |
|
FACID 20MG |
|
FACID 40MG |
|
FACID INJECTION |
|
FACID - AC |
|
HELIGO |
|
TERAPRESS -1MG |
|
TERAPRESS -2MG |
|
TERAPRESS -5MG |
|
CYSTRAN - 2.5 |
|
CYSTRAN - 5 |
|
LOMITAS |
|
CEFTAS |
|
NILOL |
|
NILOL -HD |
|
SECZOL |
|
SECZOL - DS |
|
ITASPOR |
|
FLUTINI - KIT |
|
MEFLOTAS |
|
NIMOTAS - CD |
|
ZOLAX 0.25 |
|
ZOLAX 0.5 |
|
ZOLAX 1 |
|
ZOPICON |
|
REVAC - B |
|
TYPHO - VI |
|
DICARD - 30 |
|
DICARD - 60 |
|
DICARD - SR |
|
MONIT- 10 |
|
MONIT- 20 |
|
MONIT- OD |
|
AMTAS - 2.5 |
|
AMTAS - 5 |
|
AMTAS - 10 |
|
AMTAS - AT |
|
AMTAS - AT 25 |
|
AMTAS - E |
|
AMTAS - LP |
|
CARCA - 3.125 |
|
CARCA - 6.25 |
|
CARCA - 12.5 |
|
ENAPRIL - 2.5 |
|
ENAPRIL - 5 |
|
ENAPRIL - 10 |
|
ENAPRIL - 20 |
|
ENAPRIL - HT |
|
LOSARTAS - 25 |
|
LOSARTAS - 50 |
|
LOSARTAS - HT |
|
LOVATIN - 10 |
|
LOVATIN - 20 |
|
NALTIMA |
|
SELGIN |
|
INTALITH - 150 |
|
INTALITH - 300 |
|
INTALITH - CR |
|
ZOLAX - SR 0.5 |
|
ZOLAX - SR 1 |
|
ZOLAX - SR 1.5 |
|
CERECETAM - 400 |
|
CERECETAM - 800 |
|
CERECETAM SYRUP
(100ML) |
|
CERECETAM SYRUP
(15ML) |
|
CERECETAM
INJ.(30ML) |
|
CERECETAM
INJ.(15ML) |
|
ZEN - 100 |
|
ZEN - 200 |
|
ZEN RETARD 200 |
|
ZEN RETARD 400 |
|
VALPROL CR 200 |
|
VALPROL CR 300 |
|
VALPROL CR 500 |
|
GABAPIN 300 |
|
GABAPIN 400 |
|
PHENYTAL - 30 |
|
PHENYTAL - 50 |
|
AMITONE - 10 |
|
AMITONE - 25 |
|
AMITONE - 75 |
|
CLONIL - 10 |
|
CLONIL - 25 |
|
CLONIL - 50 |
|
CLONIL - 75 SR |
|
DEPSOL PLUS |
|
DEPSOL FORTE |
|
DO-RE-ME 25 |
|
DO-RE-ME 75 |
|
SERTIMA - 50 |
|
SERTIMA - 100 |
|
FLUNIL - 10 |
|
FLUNIL - 20 |
|
FLUNIL - 60 |
|
NEOCALM - 5 |
|
NEOCALM - 10 |
|
NEOCALM PLUS |
|
NEOCALM FORTE |
|
SKIZORIL - 25 |
|
SKIZORIL - 100 |
|
TRAZONIL - 25 |
|
TRAZONIL - 50 |
|
TRAZONIL - 100 |
|
RISDONE - 1 |
|
RISDONE - 2 |
|
RISDONE - 3 |
|
RISDONE - 4 |
|
RISDONE LIQUID |
|
COMBIDOL - 1.5 |
|
COMBIDOL - 5 |
|
COMBIDOL - 10 |
|
DOVERIN - 40 |
|
DOVERIN - 80 |
|
HEPACOR |
|
CYSTRAN - 2.5 |
|
CYSTRAN - 5 |
|
INTALOL-25 |
|
INTALOL-100 |
|
SPARINTA |
|
MELONEX-7.5 |
|
MELONEX-15 |
|
KAMI-100,
KAMI-250, KAMI-500 |
|
KAMI-100 |
|
DIZEP |
|
DICLOFLAME-SR |
|
INTAFLAM-A |
CMT REPORT [Corruption, Money
laundering & Terrorism]
The
Public Notice information has been collected from various sources including but
not limited to: The Courts, India Prisons Service, Interpol, etc.
1] INFORMATION
ON DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court
Declaration :
No records exist to suggest that subject is or was the subject of any
formal or informal allegations, prosecutions or other official proceeding for
making any prohibited payments or other improper payments to government
officials for engaging in prohibited transactions or with designated parties.
3] Asset
Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record
on Financial Crime :
Charges or conviction registered
against subject: None
5] Records
on Violation of Anti-Corruption Laws :
Charges or investigation registered
against subject: None
6] Records
on Int’l Anti-Money Laundering Laws/Standards :
Charges or investigation registered
against subject: None
7] Criminal
Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation
with Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation
Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA
INFORM as part of its Due Diligence do provide comments on Corporate Governance
to identify management and governance. These factors often have been predictive
and in some cases have created vulnerabilities to credit deterioration.
Our
Governance Assessment focuses principally on the interactions between a
company’s management, its Board of Directors, Shareholders and other financial
stakeholders.
CONTRAVENTION
Subject
is not known to have contravened any existing local laws, regulations or
policies that prohibit, restrict or otherwise affect the terms and conditions
that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US
Dollar |
1 |
Rs.45.98 |
|
UK
Pound |
1 |
Rs.84.54 |
|
Euro |
1 |
Rs.57.82 |
SCORE &
RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
7 |
|
PAID-UP CAPITAL |
1~10 |
7 |
|
OPERATING SCALE |
1~10 |
7 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
7 |
|
--PROFITABILIRY |
1~10 |
7 |
|
--LIQUIDITY |
1~10 |
7 |
|
--LEVERAGE |
1~10 |
7 |
|
--RESERVES |
1~10 |
7 |
|
--CREDIT LINES |
1~10 |
7 |
|
--MARGINS |
-5~5 |
-- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
YES |
|
--AFFILIATION |
YES/NO |
YES |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
63 |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit
history (10%) Market
trend (10%) Operational
size (10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial
base with the strongest capability for timely payment of interest and
principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No
caution needed for credit transaction. It has above average (strong)
capability for payment of interest and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are
regarded healthy. General unfavourable factors will not cause fatal effect.
Satisfactory capability for payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal.
Capable to meet normal commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors
carry similar weight in credit consideration. Capability to overcome
financial difficulties seems comparatively below average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of
interest and principal sums in default or expected to be in default upon
maturity |
Limited with full security |
|
<10 |
C |
Absolute credit risk exists. Caution
needed to be exercised |
Credit not recommended |